South Africa is set to begin local production of a generic version of a new twice-yearly HIV injection drug.

This development is expected to make the advanced treatment more affordable and accessible to millions of people living with HIV across Africa.

The move will help reduce the high cost of the medication currently available.

The new drug is considered a major breakthrough in HIV treatment because patients only need to take it twice a year instead of daily pills. Local production in South Africa will significantly lower the price, making it easier for governments and health organisations to reach more patients, especially in low-income communities.

Health experts believe this step will greatly improve treatment adherence and help in the fight to control the spread of HIV. When patients can access long-acting injections more easily, it reduces the chances of missing doses and developing drug resistance.

This is expected to lead to better health outcomes across the continent.

The initiative is part of broader efforts by African countries to become more self-reliant in producing essential medicines. South Africa has a strong pharmaceutical manufacturing base, and this new generic drug production will strengthen the country’s role in supplying affordable HIV medications to other nations.

Many Nigerians and Africans living with HIV have welcomed the news with hope. If successfully produced and distributed, the generic version could transform HIV treatment by making it simpler, cheaper, and more effective.

This development marks another positive step in the global effort to end AIDS as a public health threat.